Symptoms and age of prodromal Alzheimer’s disease in Down syndrome: a systematic review and meta-analysis

被引:0
作者
Eri Shimizu
Keiko Goto-Hirano
Yumiko Motoi
Masami Arai
Nobutaka Hattori
机构
[1] Juntendo University,Department of Clinical Genetics
[2] The Medical Center for Dementia,Department of Neurology
[3] Juntendo Hospital,undefined
[4] Juntendo University,undefined
来源
Neurological Sciences | 2024年 / 45卷
关键词
Down syndrome; Alzheimer’s disease; Prodromal symptoms; BPSD;
D O I
暂无
中图分类号
学科分类号
摘要
The diagnostic criteria for adult-onset Alzheimer’s disease (AD) in patients with Down syndrome (DS) have not been standardised. This study investigated the specific symptoms of AD in the prodromal stage of DS, the mean age at diagnosis at each stage of dementia, and the relationship between intellectual disability (ID) and dementia. PubMed, Web of Science, and Embase were searched for studies on DS, AD, early-stage disease, initial symptoms, and prodromal dementia registered between January 2012 and January 2022. We also performed a meta-analysis of the differences between the mean age at prodromal symptoms and AD diagnosis and the proportion of mild cognitive impairment in patients with mild and moderately abnormal ID. We selected 14 articles reporting the behavioural and psychological symptoms of dementia (BPSD) and memory- and language-related impairments as early symptoms of AD in patients with DS. The specific symptoms of BPSD were classified into five categories: irritability (agitation), apathy, abnormal behaviour, adaptive functioning, and sleep disturbance. The mean age at the diagnosis of prodromal symptoms and AD dementia was 52.7 and 56.2 years, respectively (mean difference, + 3.11 years; 95% CI 1.82–4.40) in the meta-analysis. The diagnosis of mild dementia tended to correlate with ID severity (odds ratio [OR], 1.38; 95% CI 0.87–2.18). The features of behaviour-variant frontotemporal dementia may be clinically confirmed in diagnosing early symptoms of DS-associated AD (DSAD). Moreover, age-appropriate cognitive assessment is important. Further studies are required to evaluate DSAD using a combination of biomarkers and ID-related data.
引用
收藏
页码:2445 / 2460
页数:15
相关论文
共 139 条
  • [1] Tsou AY(2020)Medical care of adults with Down syndrome: a clinical guideline JAMA 324 1543-1556
  • [2] Bulova P(2021)Alzheimer’s disease associated with Down syndrome: a genetic form of dementia Lancet Neurol 20 930-942
  • [3] Capone G(2016)Dementia in Down’s syndrome Lancet Neurol 15 622-636
  • [4] Fortea J(2021)Astrocytes in Down syndrome across the lifespan Front Cell Neurosci 15 702685-805
  • [5] Zaman SH(2017)Elucidating pathogenic mechanisms of early-onset Alzheimer’s disease in Down syndrome patients Yakugaku Zasshi 137 801-391
  • [6] Hartley S(1995)Age-related distribution of neuropathologic changes in the cerebral cortex of patients with Down’s syndrome. Quantitative regional analysis and comparison with Alzheimer’s disease Arch Neurol 52 379-813
  • [7] Ballard C(2017)Alzheimer’s disease in people with Down’s syndrome: the prospects for and the challenges of developing preventative treatments J Neurol 264 804-147
  • [8] Mobley W(2019)Dementia in Down syndrome: unique insights for Alzheimer disease research Nat Rev Neurol 15 135-644
  • [9] Hardy W(2018)Alzheimer-like pattern of hypometabolism emerges with elevated amyloid-β burden in Down syndrome J Alzheimers Dis 61 631-1997
  • [10] Ponroy Bally B(2020)Clinical and biomarker changes of Alzheimer’s disease in adults with Down syndrome: a cross-sectional study Lancet 395 1988-70